If you’ve been taking antidepressants that once helped and now seem to have stopped working, or if you’ve tried multiple medications and never found one that adequately relieved your depression, you’re facing something that happens more often than most people realize. Antidepressant tachyphylaxis, the clinical term for when a previously effective medication appears to lose efficacy, affects some patients. Treatment-resistant depression, broadly defined as inadequate response to two or more adequate antidepressant trials, affects an estimated 30% of people with depression (McIntyre et al., 2023). At Mindful Infusions in Salt Lake City, we see patients across the Wasatch Front who are at exactly this point: medications that worked, medications that partially worked, or medications that never fully worked, and a question about what comes next.
This post is our honest, practical answer to that question. It is not a pitch for a specific treatment. It is a walk through the landscape of what options exist, what evidence supports them, and how we think about sequencing care for patients in Utah who have reached the limits of conventional antidepressants.
Why Antidepressants Sometimes Stop Working
There are several distinct clinical scenarios that can look like “antidepressants stopped working.” Understanding which one applies to you matters for what comes next.
The first is tachyphylaxis, a loss of response to a previously effective medication. The mechanisms are not fully understood, and apparent loss of benefit can have more than one cause, including changes in adherence, illness course, or other factors affecting symptoms. Estimates of how often it occurs vary by study and definition (Targum, 2014).
The second is that the medication was never fully adequate in the first place. Many patients experience partial remission: enough relief to function, but a persistent residual burden of depressive symptoms that can be easily overlooked in clinical encounters. Over time, that residual burden can accumulate and eventually feel like a relapse when it is actually a continuation of undertreated illness.
The third is that life circumstances have changed in ways that have outpaced what your current medication can address. Loss, trauma, physical illness, major life transitions, and changes in sleep can all affect depressive symptoms and may call for a treatment reassessment. Here in Utah, we’ve observed that seasonal light changes and the pressures of certain community contexts can also be part of the picture. Our blog post on ketamine for depression when antidepressants fail explores this territory in more depth.
The Next Steps After Antidepressants: What the Guidelines Say
When an antidepressant is not providing adequate relief, current guidelines recommend reassessing the treatment history and considering options such as optimizing the current regimen, switching to a different antidepressant, adding an adjunctive medication, or adding psychotherapy (Lam et al., 2024).
These steps are reasonable and appropriate, and many patients do find relief through them. But each adjustment takes time to evaluate, and the process can be genuinely demoralizing after years of effort that have already produced inadequate results. At Mindful Infusions, we see patients who have been through these steps. We take that history seriously, and we do not want to repeat a process without first understanding what has already been tried. Discuss your treatment history thoroughly with your provider so recommendations are based on where you actually are, not where you might be assumed to be.
When to Consider IV Ketamine Therapy
IV ketamine therapy, used off-label for psychiatric conditions including treatment-resistant depression, represents a different mechanism from conventional monoamine-targeting antidepressants. Where SSRIs, SNRIs, and many other antidepressants work through serotonin, norepinephrine, or dopamine, ketamine affects the glutamate system through NMDA receptor antagonism. This is associated with downstream signaling involved in synaptic plasticity and BDNF-related pathways (Duman et al., 2019).
The result is that antidepressant effects can emerge within hours for some patients, rather than over weeks. In a randomized trial of patients with treatment-resistant major depression, significant improvement after a single IV ketamine infusion was observed within hours and remained significant for up to one week (Zarate et al., 2006). For a closer look at the mechanism, read our guide to how ketamine therapy works in the brain for depression relief.
The clinical evidence supports rapid, short-term antidepressant effects for some people with major depression, including treatment-resistant depression, while also showing that response and duration of benefit vary (Nikolin et al., 2023). At Mindful Infusions, we evaluate each patient individually before recommending ketamine, reviewing psychiatric history, medications, medical history, and factors that may affect whether treatment is appropriate. We are honest about the fact that results vary by individual and that ketamine is not appropriate for everyone. But for patients who have genuinely exhausted conventional antidepressant options and are still not well, the mechanism difference that ketamine represents is precisely why it may merit consideration.
When to Consider SPRAVATO®
SPRAVATO® is FDA-approved for treatment-resistant depression in adults, either as monotherapy or in conjunction with an oral antidepressant. It is also approved for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior when used with an oral antidepressant.
If you meet the clinical criteria for one of these indications, SPRAVATO® may be an option with a level of regulatory authorization that IV ketamine does not have. It is administered as a nasal spray under clinical supervision and requires post-treatment monitoring.
One practical advantage for patients in Utah is that coverage may be available for qualifying SPRAVATO® patients. Prior authorization is common, eligibility varies by plan, and no coverage outcome can be guaranteed. At Mindful Infusions, we help patients understand the process and provide clear information about financial considerations from the first conversation.
The Honest Conversation We Have With Every Patient
When a patient comes to Mindful Infusions and tells us their antidepressants have stopped working, or never worked, we do not jump to a recommendation. We start with a thorough evaluation of the full treatment history: every medication tried, dose, duration, what happened, and what “not working” actually means for that person.
Then we have an honest conversation about options. Sometimes that conversation leads to IV ketamine. Sometimes it leads to SPRAVATO®. Sometimes it leads to a recommendation to revisit an existing regimen or pursue another step that has not been fully explored. What we always do is give you the full picture, without pressure and without false promises. Results vary by individual, and we’ll tell you what that means for your decision.
Our ketamine treatment process in Utah is designed to help you understand the practical side of care before you make a decision.
Key Takeaways
- Antidepressants can appear to stop working for several reasons, including tachyphylaxis, partial remission, and changes in life circumstances or health.
- Evidence-based next steps after inadequate antidepressant response can include optimizing treatment, switching medications, augmentation, and psychotherapy.
- IV ketamine therapy is used off-label for psychiatric conditions and works through the glutamate system, a different mechanism from conventional monoamine-targeting antidepressants.
- SPRAVATO® is FDA-approved for treatment-resistant depression and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior, with specific use requirements.
- Results vary by individual. At Mindful Infusions, we conduct a thorough evaluation before recommending any treatment so the recommendation is grounded in your specific history.
If your antidepressants have stopped working or have never fully worked, our team at Mindful Infusions in Salt Lake City is ready to have an honest conversation about what comes next. We serve patients throughout the Wasatch Front and offer evidence-based options for treatment-resistant depression. Call us at (385) 299-0473 or schedule a consultation to get started.
References
Duman, R. S., Shinohara, R., Fogaça, M. V., & Hare, B. (2019). Neurobiology of rapid-acting antidepressants. Molecular Psychiatry, 24(12), 1816–1832. https://pubmed.ncbi.nlm.nih.gov/30894661/
Lam, R. W., Kennedy, S. H., Adams, C., et al. (2024). Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults. The Canadian Journal of Psychiatry, 69(9), 641–687. https://doi.org/10.1177/07067437241245384
McIntyre, R. S., et al. (2023). Treatment-resistant depression: Definition, prevalence, risk factors, and treatment challenges. World Psychiatry, 22(3), 394–412. https://doi.org/10.1002/wps.21120
Nikolin, S., Rodgers, A., Schwaab, A., Bahji, A., Zarate, C. A., Jr., Vazquez, G., & Loo, C. K. (2023). Ketamine for the treatment of major depression: A systematic review and meta-analysis. eClinicalMedicine, 62, 102127. https://doi.org/10.1016/j.eclinm.2023.102127
Swainson, J., McGirr, A., Blier, P., et al. (2021). The Canadian Network for Mood and Anxiety Treatments Task Force recommendations for the use of racemic ketamine in adults with major depressive disorder. The Canadian Journal of Psychiatry, 66(2), 113–125. https://doi.org/10.1177/0706743720970869
Targum, S. D. (2014). Identification and treatment of antidepressant tachyphylaxis. Innovations in Clinical Neuroscience, 11(3–4), 24–28. https://pubmed.ncbi.nlm.nih.gov/24800130/
U.S. Food and Drug Administration. (2025). SPRAVATO® (esketamine) nasal spray prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf
Zarate, C. A., Jr., Singh, J. B., Carlson, P. J., et al. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry, 63(8), 856–864. https://pubmed.ncbi.nlm.nih.gov/16894061/
Medical Disclaimer
The information in this blog is for educational purposes only and does not constitute medical advice. Ketamine infusion therapy and SPRAVATO® should only be pursued under the supervision of a licensed provider familiar with your full medical and psychiatric history. Individual results vary. SPRAVATO® is FDA-approved for specific indications; IV ketamine for psychiatric conditions is used off-label. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.